Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer
Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.
Related Articles
Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease
The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.
Addition of ASCT to Ibrutinib Plus Rituximab Does Not Confer Benefit in Lower-Risk, Younger MCL
Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.
ARANOTE Features Significant rPFS Benefit of Darolutamide/ADT in mHSPC
In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.
Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma
Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.
Evolutionary cell biologist Dr. Grant King named a Hanna Gray Fellow
The Howard Hughes Medical Institute has named Fred Hutch Cancer Center postdoctoral researcher Grant King, PhD, a Hanna H. Gray Fellow — investing up to…
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
How blood and bone marrow transplant expertise is changing cancer care at Ohio State
For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis on patients’ quality of life.
FDA Fast Tracks Abenacianine for Lung Cancer Surgery
Abenacianine, a tumor-targeted fluorescent imaging agent, received fast track designation from the FDA after demonstrating its safety and efficacy in visualizing lung tumors in a…
Research Funding
AACR grants fund cancers researchers worldwide at every career stage, representing a commitment to the understanding of cancer biology, prevention, early detection, interception, and cure.
Phase 3 RCC Data Reinforce Efficacy of Standard IO/TKI Doublets Across IMDC Risk Groups
Yousef Zakharia, MD, spotlights findings from 3 key trials informing the use of standard IO/TKI regimens in metastatic clear cell renal cell carcinoma.